Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Commentary

Beta 2 antagonism in acute respiratory failure

Rob Mac Sweeney12, PJ Devereaux3 and Daniel F McAuley12*

Author Affiliations

1 Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland

2 Centre for Infection and Immunity, Health Sciences Building, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland

3 McMaster University, Faculty of Health Sciences, 1200 Main Street West, Room 2C8, Hamilton, ON, Canada, L8N 3Z5

For all author emails, please log on.

Critical Care 2010, 14:1012  doi:10.1186/cc9359


See related research by Noveanu et al., http://ccforum.com/content/14/6/R198

Published: 20 December 2010

Abstract

Post hoc analyses from the B-type natriuretic peptide for Acute Shortness of Breath Evaluation (BASEL)-II-ICU study suggest an association between beta-blocker usage at admission and improved mortality in patients treated in the intensive care unit for acute respiratory failure. Although this evidence is encouraging, there is a need for a phase 2 proof-of-concept randomized controlled trial of beta-blocker therapy in patients admitted with acute respiratory failure.